Recruiting
PHASE4
INTERVENTIONAL
NCT06857942
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) (0,1)
TimeFrame:
12 months
Description:
The DLQI is a simple, patient-reported, 10-item, validated, quality of life questionnaire. Scores range from 0 to 30, with higher scores indicating greater impairment of quality of life.
Measure:
Percentage of Participants Achieving at least 10% Weight Reduction
TimeFrame:
12 months
Description:
Percentage of participants achieving at least 10% weight reduction.
Trial Information
NCT ID
NCT06857942
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025